Alberta Investment Management Corp Purchases Shares of 94,200 Emergent Biosolutions Inc. (NYSE:EBS)

Key Points

• Alberta Investment Management Corp made a new investment of approximately $458,000 in Emergent Biosolutions Inc., acquiring 94,200 shares during the first quarter.
• Emergent Biosolutions' shares saw a 6.0% increase in value, with the stock price opening at $5.97 and a market capitalization of $323.78 million.
• Institutional investors own 78.40% of Emergent Biosolutions, indicating significant interest from large funds, including recent substantial stake increases from Covestor Ltd and SBI Securities Co. Ltd.

Alberta Investment Management Corp acquired a new position in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 94,200 shares of the biopharmaceutical company's stock, valued at approximately $458,000. Alberta Investment Management Corp owned approximately 0.17% of Emergent Biosolutions as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Covestor Ltd lifted its stake in Emergent Biosolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 2,893 shares during the period. EP Wealth Advisors LLC bought a new stake in shares of Emergent Biosolutions in the 4th quarter valued at about $110,000. Alpine Global Management LLC purchased a new stake in shares of Emergent Biosolutions in the 4th quarter worth approximately $112,000. SBI Securities Co. Ltd. lifted its position in shares of Emergent Biosolutions by 95.1% in the 1st quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 6,313 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in shares of Emergent Biosolutions during the fourth quarter valued at approximately $127,000. Institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Stock Down 0.7%

NYSE:EBS traded down $0.04 during trading hours on Wednesday, reaching $6.06. The company's stock had a trading volume of 885,690 shares, compared to its average volume of 1,214,171. The stock has a 50 day moving average price of $6.65 and a two-hundred day moving average price of $6.71. The company has a debt-to-equity ratio of 1.20, a quick ratio of 3.51 and a current ratio of 6.32. The company has a market capitalization of $328.72 million, a P/E ratio of -2.23 and a beta of 1.97. Emergent Biosolutions Inc. has a 12 month low of $4.02 and a 12 month high of $13.28.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.05). Emergent Biosolutions had a negative net margin of 13.63% and a negative return on equity of 0.52%. Equities analysts predict that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

Insider Transactions at Emergent Biosolutions

In other news, Director Keith Katkin sold 7,844 shares of the firm's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the sale, the director owned 86,431 shares of the company's stock, valued at $544,515.30. This trade represents a 8.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.20% of the company's stock.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.